Yissum and BioTheryX Sign Licensing Agreement for the Development of Next-Generation Protein Degradation and Immunomodulatory Treatment for Hematological Cancers

2021-05-19T16:06:09-07:00May 4, 2016|

CHAPPAQUA, N.Y., May 04, 2016 /PRNewswire/ -- Yissum Research Development Company of the Hebrew University of Jerusalem announced today [...]